Related Experiment Video
Updated: May 8, 2026
09:14
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
SSRI-induced coagulopathy: is it reality?
Therapeutic Advances in Psychopharmacology
|August 29, 2013
Summary
Fluoxetine, used for major depression, may increase bleeding time, while escitalopram shows no effect on coagulation. Both antidepressants are deemed safe for long-term use in patients with depression.
Area of Science:
- Pharmacology
- Psychiatry
- Hematology
Background:
- Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for major depressive disorder.
- Potential effects of SSRIs on coagulation parameters require thorough investigation for patient safety.
Purpose of the Study:
- To evaluate the impact of escitalopram and fluoxetine on the coagulation profile of patients diagnosed with major depressive disorder.
Main Methods:
- A prospective, open-label study involving 40 patients with major depressive disorder.
- Patients received either escitalopram (10 mg/day) or fluoxetine (20 mg/day) for 3 months.
- Coagulation parameters (bleeding time, clotting time, platelet count, prothrombin time, partial thromboplastin kaolin time) were assessed at baseline and after 3 months.
Main Results:
- Fluoxetine treatment resulted in a statistically significant increase in bleeding time, although values remained within the normal range.
- Escitalopram treatment did not show any significant effect on bleeding time or other coagulation parameters.
- No significant changes were observed in clotting time, platelet count, prothrombin time, or partial thromboplastin kaolin time for either drug group.
Conclusions:
- Fluoxetine may prolong bleeding time in patients with major depression, whereas escitalopram does not appear to affect the coagulation profile.
- Both escitalopram and fluoxetine are considered safe for long-term management of depression concerning coagulation parameters.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...